Inflammatory bowel disease, a chronic condition of the intestine, is associated with numerous extraintestinal manifestations, including pancreatitis. This study investigated the effect of octreotide administration on oxidative damage in a rat model of colitis induced by 2,4,6-trini-trobenzene sulfonic (TNBS) acid. Colonic and pancreatic malondialdehyde and glutathione levels are indicators of oxidative damage, and TNBS-induced colitis significantly increased the colonic and pancreatic malondialdehyde levels and decreased glutathione levels. Octreotide treatment was associated with decreased malondialdehyde levels and increased glutathione levels in the colonic and pancreatic tissue. The colonic mucosal structure was preserved and pancreatic inflammation decreased in rats treated with octreotide. Octreotide also significantly decreased nuclear factor-kB expression by immunohisto-chemistry in the colonic and pancreatic tissue compared with TNBS-induced colitis group. Octreotide appears to have protective effects against TNBS-induced colonic and pancreatic damage. These results imply the reduction in mucosal damage owing to the anti-inflammatory and antioxidant effects of octreotide.
Guarner F, Malagelada JR.Role of bacteria in experimental colitis. Best Pract Res Clin Gastroenterol. 2003; 17: 793-804.
2.
Danese S, Sans M, Fiocchi C.Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev.2004;3: 394-400.
3.
Cho C.Current roles of nitric oxide in gastrointestinal disorders. J Physiol. 2001;95: 253-256.
4.
Kankuri E, Hamalainen M, Hukkanen M, et al.Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis. Scand J Gastroenterol. 2003;38: 186-192.
5.
Stokkers P, Hommes D.New cytokine therapeutics for inflammatory bowel disease. Cytokine. 2004;28: 167-173.
6.
Ademoğlu E, Erbil Y, Tam B, et al.Do vitamin E and selenium have beneficial effects on trinitrobenzenesulfonic acid-induced experimental colitis. Dig Dis Sci. 2004;49: 102-108.
7.
Scuily RE, Mark EJ, Neely WF, Ebeling SH.Acute pancreatitis complicating inflammatory bowel disease. Lancet. 1999;240, 215-221.
Barthet M, Hastier P, Bernard JP, et al.Chronic pancreatitis and inflammatory bowel disease: true or coincidental association?Am J Gastroenterol. 1999;94: 2141-2148.
10.
Gironella M, Iovanna JL, Sans M, et al.Anti-inflamma-tory effects of pancreatitis associated protein in inflammatory bowel disease. Gut. 2005;54: 1244-1253.
11.
Jobin C, Sartor R. B.The I kappa B/NF-kappa B system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol. 2000;278: 451-462.
12.
Jobin C, Sartor R. B.NF-kappaB signaling proteins as therapeutic targets for inflammatory bowel diseases. Inflam Bowel Dis. 2000;6;206-213.
13.
Jian YT, Mai GF, Wang JD, Zhang YL, Luo RC, Fang YX.Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol. 2005;11: 1747-1752.
14.
Kido T, Sumii K, Kawano M, Sumii M, Yoshihara M, Chayama K.Food deprivation enhances somatostatin and somatostatin receptor subtype expression in rat colon. Regul Pept. 2003;114: 167-173.
15.
Low MJ.The somatostatin neuroendocrine system: physiology and clinical relevance in gastrointestinal and pancreatic disorders. Best Pract Res Clin Endocrinol Metab. 2004;18: 607-622.
Dasgupta P.Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004;102: 61-85.
18.
Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors. Mayo Clin Proc. 2005;80: 502-506.
19.
Falconi M, Pederzoli P.The relevance of gastrointestinal fistulae in clinical practice: a review. Gut. 2001;49: 2-10.
20.
Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallacei JL.Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96: 795-803.
21.
Millar AD, Rampton DS, Chander CL, et al.Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut. 1996;39: 407-415.
22.
Buege JA, Aust SD.Microsomal lipid peroxidation. Methods Enzymol. 1978;52: 302-310.
23.
Sedlak J, Lindsay RH.Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissues with Ellmann’s reagent. Anal Biochem. 1968;25: 192-205.
24.
Shusterman T, Sela S, Cohen H, Kristal B, Sbeit W, Reshef R.Effect of the antioxidant Mesna (2-mercaptoethane sulfonate) on experimental colitis. Dig Dis Sci. 2003;48: 1177-1185.
25.
Woodruff TM, Arumugam TV, Shiels IA, et al.A potent and selective inhibitor of group II a secretory phospholipase A2 protects rats from TNBS-induced colitis. Int Immunopharmacol. 2005;5: 883-892.
26.
Barthet M, Dobucquoy L, Garcia S, et al.Pancreatic changes in TNBS-induced colitis in mice. Gastroenterol Clin Biol. 2003;27: 895-900.
27.
Sener G, Sehirli AO, Satiroglu H, Kacmaz A, Ayanoglu-Dulger G, Yegen BC.Octreotide improves burn-induced intestinal injury in the rat. Peptides. 2003;24: 123-127.
28.
Kacmaz A, Polat A, User Y, Tilki M, Ozkan S, Sener G.Octreotide improves reperfusion-induced oxidative injury in acute abdominal hypertension in rats. J Gastrointest Surg. 2004;8: 113-119.
29.
Kacmaz A, Polat A, User Y, Tilki M, Ozkan S, Sener G.Octreotide: a new approach to the management of acute abdominal hypertension. Peptides. 2003;24: 1381-1386.
30.
Wang J, Zheng H, Sung CC, Hauer-Jensen M.The synthetic somatostatin analogue, octreotide, ameliorates acute and delayed intestinal radiation injury. Int J Radiat Oncol Biol Phys. 1999;45: 1289-1296.
31.
Eliakim R, Karmeli F, Okon E, Rachmilewitz D.Octreotide effectively decreases mucosal damage in experimental colitis. Gut. 1993;34: 264-269.
